Crispr Theraptc (CRSP) Receives Consensus Recommendation of “Buy” from Brokerages
Shares of Crispr Theraptc (NASDAQ:CRSP) have been given an average recommendation of “Buy” by the eight analysts that are currently covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $23.00.
A number of research firms have recently weighed in on CRSP. Chardan Capital reaffirmed a “buy” rating on shares of Crispr Theraptc in a research report on Monday, August 14th. Barclays PLC reaffirmed a “buy” rating and set a $29.00 price objective on shares of Crispr Theraptc in a research report on Friday, September 8th. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a research report on Tuesday, July 18th. Cann began coverage on Crispr Theraptc in a research report on Monday, July 17th. They set a “market perform” rating on the stock. Finally, SunTrust Banks, Inc. began coverage on Crispr Theraptc in a research report on Thursday, July 13th. They set a “hold” rating and a $16.00 price objective on the stock.
In related news, CEO Rodger Novak sold 18,470 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $20.76, for a total value of $383,437.20. Following the transaction, the chief executive officer now directly owns 1,148,007 shares of the company’s stock, valued at approximately $23,832,625.32. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Samarth Kulkarni sold 27,154 shares of the business’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $20.08, for a total value of $545,252.32. Following the completion of the transaction, the insider now directly owns 110,893 shares in the company, valued at $2,226,731.44. The disclosure for this sale can be found here. Over the last three months, insiders sold 523,764 shares of company stock worth $10,021,502. 39.98% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN lifted its holdings in Crispr Theraptc by 459.7% in the 2nd quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock worth $128,000 after purchasing an additional 6,560 shares in the last quarter. ARK Investment Management LLC purchased a new position in Crispr Theraptc in the 2nd quarter worth approximately $206,000. Moloney Securities Asset Management LLC purchased a new position in Crispr Theraptc in the 3rd quarter worth approximately $235,000. Vanguard Group Inc. purchased a new position in Crispr Theraptc in the 2nd quarter worth approximately $273,000. Finally, Credit Suisse AG purchased a new position in Crispr Theraptc in the 1st quarter worth approximately $1,742,000. 23.90% of the stock is currently owned by institutional investors.
Shares of Crispr Theraptc (NASDAQ:CRSP) opened at 19.07 on Friday. The company’s market capitalization is $774.07 million. The stock’s 50 day moving average price is $18.70 and its 200 day moving average price is $18.70. Crispr Theraptc has a 12 month low of $13.90 and a 12 month high of $25.00.
Crispr Theraptc (NASDAQ:CRSP) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($0.56) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.62) by $0.06. Crispr Theraptc had a negative return on equity of 47.46% and a negative net margin of 406.61%. The firm had revenue of $3.60 million for the quarter, compared to analysts’ expectations of $3.29 million. The firm’s revenue was up 350.0% on a year-over-year basis. On average, analysts forecast that Crispr Theraptc will post ($2.43) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Crispr Theraptc (CRSP) Receives Consensus Recommendation of “Buy” from Brokerages” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/21/crispr-theraptc-crsp-receives-consensus-recommendation-of-buy-from-brokerages.html.
About Crispr Theraptc
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.